April 4, 2017 08:34 AM EDT

Bristol-Myers joins the IDO rush with its own in-house combo program for Opdivo

John Carroll

Editor & Founder

WASHINGTON, DC — While Bristol-Myers Squibb joined the rush to partner with Incyte on its leading IDO1 drug epacadostat, it’s also been zeroing in on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol-Myers joins the IDO rush with its own in-house combo program for Opdivo

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Bristol Myers sues the federal government over 340B, following other drugmakers

Bris­tol-My­ers joins the IDO rush with its own in-house com­bo pro­gram for Op­di­vo

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Bristol-Myers joins the IDO rush with its own in-house combo program for Opdivo

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Bristol Myers sues the federal government over 340B, following other drugmakers